Asset 22.png

Robert Schnepp

Emory University
Atlanta, GA, USA

CBTN Specimen


CBTN Participants

CBTN Pre-clinical Models


Institutional Funds

About this


The Schnepp laboratory focuses on aggressive solid tumors including high-risk neuroblastoma, rhabdomyosarcoma and medulloblastoma. Adult tumors of these types tend to have more mutations that can in turn be targeted by therapies than their pediatric counterparts. This verifies the need to identify additional druggable targets in the pediatric forms of these tumors. Previous laboratory work has identified the RNA-binding proteins (RBP) LIN28B and Musashi 2 (MSI2) as drivers of neuroblastoma. This leads researchers to believe that RBPs may be involved in other cancers as well. Prior studies have identified several RBPs as crucial to tumor development in medulloblastoma cell lines. Based on this preliminary data, researchers hypothesize that RBPs may play critical roles in medulloblastoma development. This project aims to be a comprehensive investigation of the role of RBPs, with the eventual goal of nominating targets for the treatment of these tumors and others. Access to cell lines from the Children’s Brain Tumor Network allows researchers to assess RBP vulnerabilities in as many models as possible, increasing the efficiency and impact of this project.

Ask The


Ask the scientists

What are the goals of this project?

This project aims to investigate the role of RNA binding proteins (RBPs) in the development of pediatric tumors including medulloblastoma.

What is the impact of this project?

Compared to their adult counterparts, pediatric cancers have fewer mutations that can be targeted for therapies, so the exploration of RBPs will open a new avenue of treatments for these tumors.

Why is the CBTN request important to this project?

The cell lines provided by the Children’s Brain Tumor network allow researchers a wide range of models for use in this project.

Specimen Data

The Children's Brain Tumor Network will contribute to this project by providing cell lines.

Meet The



Robert Schnepp, MD, PhD

Pediatric Oncology Research ProgramCell and Molecular Biology


Emory University

Atlanta, GA, USA

Anna M. Kenney, PhD

Dr. Kenney's research focuses on cell cycle control in cerebellar development and medulloblastoma, a pediatric brain tumor that arises in the cerebellum. These tumors are the most common solid malignancy of childhood. Current treatments for medulloblastomas include surgical resection, chemotherapy,


Emory University

Atlanta, GA, USA

Shubin Shahab, MD, PhD

Neuro-Oncology Instructor


Emory University

Atlanta, GA, USA

Scientific Committee

Executive Board

Scientific co-Chair

Principal Investigator

Adam Resnick, PhD

Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is a


Children’s Hospital of Philadelphia

Philadelphia, PA, USA

Michael Taylor, MD, PhD, FRCS(C)

Dr. Taylor’s laboratory plans to use the tools of forward and reverse genetics to better understand the underlying biology of medulloblastoma and ependymoma, two of the most common malignant paediatric brain tumours.In forward genetic approaches, the normal cells that are thought to give rise to a c


Sick Kids

Toronto, Canada

Tobey J. MacDonald, MD

Dr. MacDonald's research areas of interest include basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGFR) signaling basic and translational research of childhood brain tumors with a primar


Emory University

Atlanta, GA, USA